Allergan, Shire autoimmune news
The U.S. District Court for the District of Southern Florida upheld a patent protecting Shire’s ulcerative colitis drug Lialda mesalamine and granted an injunction blocking approval and sale of a generic form of the drug from Allergan until the patent expires on June 8, 2020. It is the only Orange Book-listed patent for Lialda. In the suit, Shire alleged that an ANDA submitted by Watson Pharmaceuticals Inc., which is now part of Allergan, infringed Shire’s U.S. Patent No. 6,773,720. The same district court had found in favor of Shire in 2013 as well. The case was twice appealed, to the U.S. Court of Appeals for the Federal Circuit (CAFC) and the U.S. Supreme Court, but it was remanded back to the district court on jurisdictional grounds. ...